Introduction {#Sec1}
============

Down syndrome (DS), known as the most frequent chromosomal abnormality, is caused by an extra chromosome 21 or a fragment thereof^[@CR1]^. According to the National Institute of Child Health & Human Development (<http://www.ncbi.nlm.nih.gov/pubmed/>) the incidence of DS in the United States is estimated to be 1:800-1:1.000 live births. This trisomy concerns congenital anomalies, including heart defects, gastrointestinal anomalies, immune system defects, thyroid disease, bone defects, genitourinary system defects, intellectual disability and many other diseases^[@CR2]^. Currently, prenatal diagnosis of DS is based on invasive techniques that verify the occurrence of chromosomal aberration, while non-invasive methods are used to estimate the risk. Since amniocentesis as an invasive approach is associated with 1% risk of foetal damage or miscarriage^[@CR3]^, the focus of research community has been placed recently on the discovery of biomarkers, allowing for a non-invasive foetal DS diagnosis. A significant breakthrough in this field was made, when genetic testing of free foetal DNA (ffDNA), circulating in maternal peripheral blood, was developed and brought to the market. However, despite considerably low false positive rates for DS screening (0.5%), these diagnostic kits are still highly priced^[@CR4]--[@CR8]^. All mentioned prenatal diagnostic methods are focused on cytogenetic confirmation of the abnormal karyotype. In fact, we have to realize that, on the one hand, the abnormal foetal karyotype can be diagnosed in cytogenetic studies, but on the other hand, we can potentially find some biochemical variations in maternal plasma, which appeared due to stimulation by the extra chromosome 21.

MicroRNAs (miRNAs) form a large group of small non-protein coding RNAs, which are considered important regulators of gene expression^[@CR9]^. The miRNA genes are located in both coding and non-coding regions of the genome. They exert their regulatory function through the interaction of their "seed" sequences with 3′-end, and more rarely with 5′-end, of mRNA transcribed from target genes, followed by degradation of target mRNA. The reduction in the amount of a specific mRNA is an important result of this molecular event. MiRNAs have diverse expression patterns and might regulate various developmental and physiological processes^[@CR10],[@CR11]^. These short RNAs have been implicated in the widespread control of critical biological processes such as proliferation, differentiation, and apoptosis. Moreover, abnormal miRNA expression is associated with the development of various diseases, such as cancer, cardiovascular disease, metabolic disorders, intellectual disability, and trisomy 21.

Since miRNA plays a pivotal role in the epigenetic regulation of mRNA expression, it has become a target of research directed towards the development of a new non-invasive method for foetal DS screening. The diversity of miRNAs expression in trisomy 21 was already reported, but the published data are not consistent^[@CR12]^. Up to date, alterations in miRNAs expression in DS have been investigated focusing mainly on miRNAs derived from human chromosome 21. On the other hand, though, taking into consideration the complexity of epigenetic gene expression regulation, miRNAs derived from chromosomes other than chromosome 21, are likely to be involved as well. It has been previously reported that miRNA can regulate a large number of protein-coding genes, and multiple miRNAs can regulate a single target gene^[@CR13]^. Therefore, we decided to use the NanoString technology to evaluate expression pattern of 800 miRNA molecules encoded on different chromosomes. nCounter miRNA panel content is based on miRBase, a bioinformatics repository for small RNA sequence and annotation information^[@CR14]^. The results of our analysis could yield information on miRNA expression patterns specific for DS. Our study might not only identify molecules potentially involved in disorder pathogenesis, but most importantly help to design a panel for non-invasive DS screening.

Results {#Sec2}
=======

Identification of a serum miRNA profile for foetal Down syndrome {#Sec3}
----------------------------------------------------------------

To identify miRNAs with potential diagnostic value, we performed miRNA profiling of plasma from DS patients (n = 12) and healthy control subjects (n = 12), using the NanoString Technology platform. The clinical characteristics of all participants is presented in Table [1](#Tab1){ref-type="table"}. The group of 13 miRNAs with the most significant differences in expression between the two compared groups (p \< 0.05 = the unadjusted *p* value) was selected using a t test. Specifically, 6 miRNAs were upregulated (hsa-miR-15a, hsa-let-7d, hsa-miR-142, hsa-miR-23a, hsa-miR-199, hsa-miR-191) and 7 downregulated (hsa-miR-1290, hsa-miR-1915, hsa-miR30e, hsa-miR-1260, hsa-miR-483, hsa-miR-548, hsa-miR-590) in plasma samples of DS patients versus healthy control subjects (Table [2](#Tab2){ref-type="table"}).Table 1Clinical characteristics of the patients.Down Syndrome Pregnancies (n = 12)Pregnancies without Down Syndrome (n = 12)*p* valueMaternal age (mean ± SD)38,5 ± 2,9538 ± 4,170,17Body mass index (kg/m^2^) (mean ± SD)23,75 ± 2,6523,58 ± 3,320,46Gestational age (mean ± SD)16 ± 1,0717 ± 1,190,54SD - standard deviation.The *p* value describes significance of difference between women with foetal Down syndrome (DS) in comparison to healthy controls using Mann-Whitney U-test.Table 2miRNAs upregulated and downregulated in DS group.miRNA IDCounts in DS groupCounts in control groupFold change*p* valueGenome contexthsa-miR-15a-5p42,28 ± 13,6323,81 ± 15,35**1**,**78 ↑**0,0013Chr13hsa-let-7d-5p115,26 ± 91,6966,72 ± 41,87**1**,**73 ↑**0,0226Chr9hsa-miR-142-3p185,16 ± 84,58114,81 ± 107,95**1**,**61 ↑**0,0349Chr17hsa-miR-23a-3p322,96 ± 180,07198,01 ± 67,98**1**,**63 ↑**0,0371Chr19hsa-miR-199a-3p214,61 ± 51,64135,35 ± 39,56**1**,**59 ↑**0,0431Chr19hsa-miR-191-5p235,33 ± 205,31123,13 ± 81,62**1**,**91 ↑**0,0481Chr3hsa-miR-129053,27 ± 18,1295,84 ± 40,14**1**,**81 ↓**0,0018Chr1hsa-miR-1915-3p10,63 ± 6,8919,69 ± 7,83**1**,**85 ↓**0,0068Chr10hsa-miR-30e-5p49,37 ± 10,9462,96 ± 12,17**1**,**28 ↓**0,0097Chr1hsa-miR-1260a11,05 ± 4,2615,84 ± 5,85**1**,**43 ↓**0,026Chr14hsa-miR-483-3p14,44 ± 5,1419,35 ± 5,8**1**,**34 ↓**0,031Chr11hsa-miR-548n29,97 ± 10,3145,15 ± 13,05**1**,**52 ↓**0,043Chr7hsa-miR-590-5p19,63 ± 7,9928 ± 10,5**1**,**43 ↓**0,046Chr7The *p* value describes significance of difference between women with foetal Down syndrome (DS) in comparison to healthy controls using nSolver Software; miRNA ID = official microRNA name according to miRBASE; *p* value = the unadjusted *p* value from the t test.

Putative targets genes for miRNAs {#Sec4}
---------------------------------

To examine the function of miRNAs identified as potential biomarkers for DS, we revealed putative target genes for each of the differentially expressed molecules using Ingenuity Pathway Analysis, a tool for analysis, integration and interpretation of data derived from 'omics' experiments. That powerful data integration allows to uncover the significance of data and identify new targets or create the interactive network within the context of biological systems^[@CR15]^. Based on this tool we proposed a new integrative network including target genes and miRNAs (Fig. [1](#Fig1){ref-type="fig"}). The genes selected as potentially regulated by selected miRNAs were divided into 7 functional clusters using DAVID Functional Annotation Clustering Tool integrated in DAVID Bioinformatics Resources^[@CR16]^. Disease association analysis was performed using IPA. Cancer pathway were identified as the most highly affected, then pathway connected with reproductive system disease, organismal injury and abnormalities, hematological disease and immunological processes.Figure 1The highest scoring miRNA-mRNA interaction network were generated through the use of IPA (QIAGEN Inc., <https://www.qiagenbio-informatics.com/products/ingenuity-pathway-analysis>).

Discussion {#Sec5}
==========

The growing number of studies examining the global changes in miRNA expression suggest that these molecules are associated with a variety of human diseases, such as neuropsychiatric disorders^[@CR17]^, diabetes^[@CR18]^ and cancer^[@CR19]^. The expression levels of biofluids--derived miRNAs represent potential novel tools for diagnostic and disease activity assessment purpose^[@CR20]^. Although several technological options are available to analyse miRNA expression comprehensively, the detection of miRNAs in and subsequent interpretation of such data can be strongly influenced by the specific platforms used. In our study, we focused on a comparison of miRNA expression profiles between maternal plasma samples from pregnant women with euploid or T21 foetuses. We hypothesized that the plasma-derived miRNAs could potentially represent novel means for the prenatal non-invasive diagnosis of foetal Down syndrome. To our best knowledge, this study is the first miRNA profiling in plasma maternal sample based on NanoString nCounter platform. Above platform has been shown in comparison test to detect miRNAs in biofluids with greater sensitivity and specificity than other miRNA detection methods and offers high quality data due to the limited RNA amplification that could potentially introduce bias toward the most abundant miRNAs^[@CR21]^.

Our study revealed that 13 miRNAs are differentially expressed in women with foetal Down syndrome in comparison to healthy donors. Despite selected miRNAs were exceed FDR-corrected criterion, we believe that the candidates miRNAs have a high probability of being specific for plasma pregnant women with T21 foetuses. Previous study have shown the involvement of five chromosome 21- derived miRNAs using real-time PCR assay and they observed no differences between pregnant women with euploid or Down syndrome foetuses^[@CR22]^.

Erturk *et al*. evaluated 14 chromosome 21-derived miRNAs in maternal plasma and found increased levels of miR-99a and miR-3156, when compared to patients carrying euploid foetuses^[@CR23]^. Lim *et al*. reported altered expression of placenta -- specific miRNAs, miR -- 1973 and miR -- 3196 were overexpressed in trisomy 21 placenta. These two miRNAs may regulate target genes involved in development of the nervous system^[@CR24]^. This data suggests that miRNA profiling may be a promising strategy in the development of non-invasive prenatal testing. Moreover, researchers highlighted the importance of the assessment of other miRNAs related to chromosome 21.

The expression levels of miRNAs were also investigated in DS individuals. Xu *et al*. identified overexpressed miR-99a in lymphocytes, linking this observation to immunological defects in trisomy 21^[@CR12]^. The investigators focused on searching for the differences in miRNA expression in villus samples. However, they analysed only maternal blood of patients with euploid foetus, but not with foetal DS. Shi *et al*.^[@CR25]^ studied the miRNA expression profile of hippocampal tissue from DS foetuses using miRNA microarray, and reported that the function of miR-138-5p and the downregulation of its target, enhancer of zeste homolog 2, in the hippocampus may be involved in the intellectual disability of DS patients. A pregnancy with a DS foetus is accompanied by a great number of biochemical variations in maternal plasma, probably induced by the additional chromosome 21. The latest reports show that pregnancies with foetal chromosomal aberrations are strongly connected with imbalance in chemokines and bioactive lipids, such as sphingolipids. It indicates a new potential biological mechanism of foetal DS^[@CR26]--[@CR30]^.

We hypothesize that the additional foetal chromosome 21 could potentially have an impact on the expression of miRNAs encoded on different pairs of chromosomes as well.

Since the pathology of the syndrome is extremely complicated and the additional chromosome 21 causes multiple foetal pathologies and induces maternal immune response, searching for abnormal signals and understanding the pathological mechanism are highly desired. For that purpose, differentially expressed miRNA molecules were analysed using bioinformatics tools to explore their biological function (Fig. [1](#Fig1){ref-type="fig"}). As shown Table [3](#Tab3){ref-type="table"}, the target genes regulated by miRNAs characterised in T21 are involved in the central nervous system development, congenital abnormalities, heart defects.Table 3Functional annotation clustering according to DAVID Functional Annotation Clustering Tool integrated in DAVID Bioinformatics Resources.Gene cluster 1TIA1TIA1 cytotoxic granule associated RNA binding proteinRBMS1RNA binding motif single stranded interacting protein 1IGF2BP3Insulin like growth factor 2 mRNA binding proteinNCLNucleolinHNRNPA0Heterogenous nuclear ribonucleoprotein A0RBM19RNA binding motif protein 19**Gene cluster 2**MAP4K4Mitogen-activated protein kinase 4MAPKAPK2Mitogen-activated protein kinase-activated protein kinase 2WEE1WEE1 G2 checkpoint kinaseBMP2KBMP2 inducible kinaseHIPK3Homeodomain interacting protein kinaseCHEK1Checkpoint kinase 1**Gene cluster 3**KRT85Keratin 85KRT19Keratin 19LMNB1Lamin B1VIMVimentinKRT7Keratin 7LMNB2Lamin B2**Gene cluster 4**RAB21Member RAS oncogene familyRHOGRas homolog family memberRAB9BMember RAS oncogene familyRHOBRas homolog family memberRAB30Member RAS oncogene familyRAB27BMember RAS oncogene family**Gene cluster 5**CDCP1CUB domain containing protein 1SLC16A10Solute carrier family 16 member 10SLC7A11Solute carrier family 7 member 11SLC38A1Solute carrier family 38 member 1SLC7A1Solute carrier family 7 member 1SLC38A5Solute carrier family 38 member 5SLC38A2Solute carrier family 38 member 2**Gene cluster 6**SLC25A1Solute carrier family 25 member 1SLC25A32Solute carrier family 25 member 32SLC25A24Solute carrier family 25 member 24UCP2Uncoupling protein 2SLC25A13Solute carrier family 25 member 13SLC25A22Solute carrier family 25 member 22**Gene cluster 7**CLDN12Claudin 12TMEM251Transmembrane protein 251C2orf74Chromosome 2 open reading frame 74C17orf80Chromosome 17 open reading frame 80TVP23BTrans-golgi network vesicle protein 23 homolog BTMEM59Transmembrane protein 59RFT1RFT1 homologCA12Carbonic anhydrase 12TMEM87ATransmembrane protein 87ATMEM106CTransmembrane protein 106CSLC8A5Solute carrier family 8 member 5TMEM41BTransmembrane protein 41BNIPAL2NIPA like domain containing 2FAM69AFamily with sequence similarity 69 member ACDCP1CUB domain containingACP2Acid phosphatase 2, lysosomalSLC35B3Solute carrier family 35 member B3PRRG4Proline rich and Gla domain 4YIF1BYip1 interacting factor homolog B, membrane trafficking protein

Our results provide a new perspective for the pathomechanism of the foetal trisomy 21 and a novel direction for future research of molecular pathways involved in the disorder. However, these data should be viewed as preliminary, we believe that it opens the new possibility that the miRNAs are novel noninvasive biomarkers. The expression patterns of miRNAs in Down syndrome pregnancies may have the crucial role for further improvement of prenatal screening.

Methods {#Sec6}
=======

Study subjects {#Sec7}
--------------

The study and control groups consisted of 198 women (mean age 33.4 yrs, range: 17--45 yrs) who underwent routine amniocentesis between the 15^th^ and 18^th^ weeks of gestation at the Department of Reproduction and Gynaecological Endocrinology of the Medical University of Bialystok, Poland. Participants received detailed information on the study and associated risks prior to enrolment. Maternal serum samples were collected directly after amniocentesis, centrifuged and stored at −80 °C. After chromosomal analyses, 12 patients with foetal trisomy 21 and 12 women (Table [1](#Tab1){ref-type="table"}) with foetal normal karyotype were qualified for the study. Women with any pathology of pregnancy, such as hypertension, diabetes or inflammatory diseases, were excluded. All study participants provided written informed consent and received detailed information on the study and associated risks prior to enrolment. The methods were carried out in accordance with the approved guidelines and was conducted in accordance with the ethical standards of the institutional research committee, with the 1964 Helsinki declaration and was approved by the local ethics committee of the Medical University of Bialystok, Poland (approval number: R-I-002/36/2014).

Detection of miRNA profile {#Sec8}
--------------------------

miRNAs were isolated from serum samples using the miRNeasy Serum/Plasma Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. The samples were prepared for nCounter miRNA expression profiling according to the manufacturer's recommendations (NanoString). Briefly, 3 ng miRNA samples were prepared by ligating a specific miR-tag onto 3′ end of each mature miRNA followed by an overnight hybridization (65 °C) to nCounter Reporter and Capture probes. Subsequently, samples were placed into the nCounter Prep Station for automated sample purification and subsequent reporter capture. Each sample was scanned on the nCounter Digital Analyzer for data collection.

Data Analysis {#Sec9}
-------------

Statistical analyses were performed with the Statistica software (version 13.1). All data were presented as means ± SD. Mann-Whitney *U* test was used to examine the statistical difference in clinical parameters between samples derived from healthy control subjects and patients with DS foetuses. nSolver 4.0 Analysis software (NanoString) was used for data analysis including normalization using the average geometric mean of the top 100 probes detected. T test with Benjamini-Hochberg false discovery rate correction for multiple comparison were used to determine differential miRNA expression.

miRNA targets prediction and functional annotation of the selected miRNA targets {#Sec10}
--------------------------------------------------------------------------------

To examine the functions of miRNAs identified, miRNA target prediction was performed using Ingenuity Pathway Analysis (QIAGEN Inc., <https://www.qiagenbioinformatics.com/products/ingenuity>- pathway-analysis). In addition, IPA was used to create the interactive network based on the selected genes list and miRNAs. Functional annotation clustering was carried out using DAVID 6.8 (Database for Annotation, Visualization and Integrated Discovery, <https://david.ncifcrf.gov/>). The DAVID analysis allows to associate the given gene list with specific functional annotations, which are further divided into the functional clusters listed according to an enrichment *p* value. The Bonferroni correction was used to control the false discovery rate.
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